1	Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test									
2										
3	Carmen W.E. Embregts ¹ , Babs Verstrepen ² , Jan A.M. Langermans, ^{2,3} , Kinga P. Böszörményi ²									
4	Reina S. Sikkema ¹ , Rory D. de Vries ¹ , Donata Hoffmann ⁴ , Kerstin Wernike ⁴ , Lidwien A.M.									
5	Smit ^o , Shan Zhao ^o , Barry Rockx ¹ , Marion P.G. Koopmans ¹ , Bart L. Haagmans ¹ , Thijs Kuiken ¹ ,									
7										
8										
9	¹ Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands									
10	² Biomedical Primate Research Centre, Rijswijk, the Netherlands									
11	³ Department Population Health Sciences, Division Animals in Science and Society, Faculty of									
12	Veterinary Medicine, Utrecht University, Utrecht, The Netherlands									
13	⁴ Institute of Diagnostic Virology, Friedrich-Loeffler-Institute, Insel Riems, Germany									
14	⁵ Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands									
15	⁶ Department of Biomolecular Health Sciences, Virology Division, Faculty of Veterinary									
16	Medicine, Utrecht University, the Netherlands									
17										
18	Corresponding authors: Corine H. GeurtsvanKessel (c.geurtsvankessel@erasmusmc.nl),									
19	Carmen W.E. Embregts (c.embregts@erasmusmc.nl)									

20 Abstract

21 Assays to measure SARS-CoV-2-specific neutralizing antibodies are important to monitor seroprevalence, to study asymptomatic infections and to reveal (intermediate) hosts. A recently 22 developed assay, the surrogate virus-neutralization test (sVNT) is a quick and commercially 23 available alternative to the "gold standard" virus neutralization assay using authentic virus, and 24 25 does not require processing at BSL-3 level. The assay relies on the inhibition of binding of the receptor binding domain (RBD) on the spike (S) protein to human angiotensin-converting 26 27 enzyme 2 (hACE2) by antibodies present in sera. As the sVNT does not require species- or isotype-specific conjugates, it can be similarly used for antibody detection in human and animal 28 29 sera. In this study, we used 298 sera from PCR-confirmed COVID-19 patients and 151 sera from patients confirmed with other coronavirus or other (respiratory) infections, to evaluate the 30 performance of the sVNT. To analyze the use of the assay in a One Health setting, we studied 31 32 the presence of RBD-binding antibodies in 154 sera from nine animal species (cynomolgus and rhesus macaques, ferrets, rabbits, hamsters, cats, cattle, mink and dromedary camels). The 33 34 sVNT showed a moderate to high sensitivity and a high specificity using sera from confirmed 35 COVID-19 patients (91.3% and 100%, respectively) and animal sera (93.9% and 100%), however it lacked sensitivity to detect low titers. Significant correlations were found between 36 37 the sVNT outcomes and PRNT₅₀ and the Wantai total Ig and IgM ELISAs. While speciesspecific validation will be essential, our results show that the sVNT holds promise in detecting 38 39 RBD-binding antibodies in multiple species.

40

42 SARS-CoV-2, serology, neutralizing antibodies, surrogate virus neutralization test, animal sera
43

⁴¹ **Keywords** (max 6)

44 Introduction

45 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) likely originates from an animal reservoir as a result of a direct spill-over event or via an intermediate mammalian host, 46 47 similar to the related zoonotic betacoronaviruses SARS-CoV and MERS-CoV [1,2]. Phylogenetic analysis revealed that SARS-CoV-2 is ancestrally linked to betacoronaviruses 48 49 found in bats [3] and pangolins [4], however, the definitive virus origin and intermediate host(s) 50 remain unidentified. Besides efficiently infecting humans, SARS-CoV-2 has been detected in 51 a wide range of animals, including farmed mink across Europe and the USA [5–7], domestic animals including cats and dogs [8-10], and several zoo felids [11]. Alarmingly, infections in 52 53 all these species could be traced back to SARS-CoV-2 infected humans, indicating a risk for reverse zoonotic events and possible SARS-CoV-2 animal reservoirs [7,12]. Furthermore, 54 55 infection experiments show that many more animal species, including non-human primates 56 [13,14], ferrets [15,16], rabbits [17], hamsters [18,19], and human angiotensin-converting enzyme 2 (hACE2) transgenic mice [20] are permissive to the virus, while other animals 57 58 including pigs and chickens are not [21,22]. The large number of permissive species and the 59 potential risks of additional (reverse) zoonotic events clearly indicate that a One Health approach is required to gain insights into the circulation of SARS-CoV-2 in humans and 60 61 epidemiologically connected animal host populations, which is essential for the prevention or 62 mitigation of further spread.

Assays to reliably detect SARS-CoV-2 specific antibodies across species are urgently needed,
for example to investigate seroprevalence and asymptomatic infections, for vaccination studies
in humans and animals, and for the identification of natural reservoirs and intermediate hosts.
Tremendous efforts in the rapid development of serological tools yielded a broad range of
assays to determine SARS-CoV-2 specific antibodies, including (high throughput) ELISAs and
lateral flow assays targeting various SARS-CoV-2 epitopes [23–25]. Total serum antibodies

are indicative for exposure, however, quantifying neutralizing antibodies is more informative. 69 70 A commonly used gold standard for detecting SARS-CoV-2 neutralizing antibodies is the 50percent plaque-reduction neutralization test (PRNT₅₀). This test requires handling of wild-type 71 72 viruses by BSL3-level trained personnel, is not suitable for high-throughput, and results are available after multiple days. Furthermore, minor differences in virus stocks and cell lines 73 complicate the intra-laboratory standardization. While pseudotyped viruses allow for 74 75 performing PRNT₅₀ tests at a BSL-2 safety level [26,27], and recombinant nanoluciferase 76 SARS-CoV-2 allows for a rapid assay protocol [28], these assays still rely on infectious viruses and cell cultures. 77

78 The first surrogate virus neutralization test (sVNT) was commercialized in 2020 [29]. This assay relies on specific binding of recombinant SARS-CoV-2 receptor binding domain (RBD) 79 to recombinant ACE2 coated on 96-wells plates, and blocking of this binding by RBD-specific 80 81 serum antibodies. The assay can be performed at any BSL-2 laboratory and yields results in only few hours. Furthermore, the assay allows for high sample-throughput, as samples are 82 83 analyzed in one defined dilution and no serial dilution is required. Validation studies showed high specificity and sensitivity of the assay [29–31], however, a recent study demonstrated low 84 sensitivity in sera with low neutralizing titers and only moderate linearity with the PRNT₅₀ [32]. 85 86 While conventional ELISAs often rely on species- and isotype-specific conjugates, the sVNT 87 assay detects RBD-binding antibodies and can potentially be used for a wide range of species. In contrast to the large number of tests developed for human sera, serological SARS-CoV-2 88 assays for other species are limited to the PRNT₅₀, few multi-species ELISAs [16,33,34], and 89 90 mouse-, guinea pig-, rabbit-, and primate-specific competition ELISAs [35,36].

91 To date, only few studies assessed the use of the described sVNT in animals (mice, rabbits, 92 ferrets, cats and hamsters) [29,30]. While these studies showed that the sVNT is capable of 93 detecting RBD-specific antibodies in the mentioned animal species, only limited numbers of

94 SARS-CoV-2 antibody positive sera were included. Here, we evaluate the performance of the 95 sVNT on human sera using 298 serum samples from a COVID-19 patient cohort, 151 sera from 96 patients diagnosed with related human coronaviruses and other (respiratory) viruses and 97 pathogens. In addition, we investigate the use of the sVNT on 154 serum samples from nine 98 different animal species.

100 Materials and methods

101

102 Human serum samples

103 All human sera used in this study were collected for routine patient diagnostics. Sensitivity analysis was performed using a panel of 298 sera of 165 PCR-confirmed COVID-19 patients. 104 105 Disease severity ranged from mild (non-hospitalized) to severe (admitted to the ICU), and samples were taken at various days post disease onset (dpd), ranging from 0-74 days 106 107 (Supplementary table 1). Specificity analysis was performed using a panel of 151 sera from 108 individuals exposed to other human coronaviruses (HCoV-229E (n=19), HCoV-NL63 (n=18), HCoV-OC43 (n=36), or MERS-CoV (n=5)), other respiratory viruses (adenovirus (n=6), 109 bocavirus (n=2), human metapneumovirus (HMPV, n=9), influenza virus A (n=10) and B 110 (n=6), human orthopneumovirus/ respiratory syncytial virus (RSV) A (n=5) and B (n=4), 111 112 rhinovirus (n=9), para-influenza virus 1 (n=4) and 3 (n=4), enterovirus (n=2)), or patients with recent cytomegalovirus (CMV, n=4), Epstein Barr virus (EBV, n=7) or Mycoplasma 113 pneumoniae (M. pneumoniae, n=1) infection. All sera were stored at -20 °C and were heat-114 inactivated at 56 °C for 30 minutes prior to analysis. 115

116

117 Animal serum samples

Animal sera were obtained after natural infections or during infection or vaccination experiments. In total 154 sera of nine different species (cynomolgus and rhesus macaques, ferrets, rabbits, hamsters, cats, cattle, mink and dromedary camels) were included in the validation study, of which 66 tested positive for SARS-CoV-2 antibodies by PRNT₅₀ (Supplementary table 2). SARS-CoV-2 antibody status of the cat sera was determined by a pseudotype VSV neutralization (VN) assay [37]. Sera from SARS-CoV-2 negative animals

were included to test the specificity of the assay. A set of possible cross-reactive sera from
MERS-CoV infected macaques and dromedary camels was included as well.

- 126
- 127 Ethics

The use of human specimens was approved by the Erasmus MC medical ethical committee (MEC approval: 2014–414), which allows the use of clinical data and left-over material from the specimen delivered to our laboratory for diagnostics, unless patients have declared they opted out of this scheme.

Animal sera were obtained as left-over material from various infection experiments or field studies (mink and cats). Specific approval was obtained for each set of sera and can be found in the referred articles. Additional non-human primate sera were obtained from various experiments that were approved by the Dutch Central Committee for Animal Experiments (license: AVD5020020209404). Mink and cat sera were obtained by a certified veterinarian during a SARS-CoV-2 outbreak at a mink farm in the Netherlands.

138

139 **PRNT**₅₀ / VSV pseudotype VN

140 The 50-percent plaque-reduction neutralization test (PRNT₅₀) was used as the gold standard in 141 this study and was performed as described before [38]. The PRNT₅₀ titer was defined as the 142 reciprocal value of the highest serum dilution resulting in 50% plaque reduction. Serum titers 143 of \geq 20 were defined as SARS-CoV-2 seropositive.

The pseudotype VN assay was performed as described recently [37] with some minor modification: serum samples were twofold diluted (starting at 1:8) and mixed 1:1 with SARS2-VSV. Mixtures were pre-incubated at 37°C for one hour and were afterwards used for inoculation of cells. Twenty-four hours post infection, the cells were lysed and relative luminescence units (RLU) of luciferase activity was determined. The sample neutralization

titers were defined by the reciprocal of the highest dilution that resulted in >50% reduction of
luciferase activity (IC50 titer).

151

152 Wantai Ig/IgM

Detection of anti-RBD antibodies was performed using the Wantai SARS-CoV-2 total Ig or IgM ELISAs (Beijing Wantai Biological Pharmacy Enterprise), which are sandwich ELISAs coated with recombinant RBD. The ELISAs were performed according to the manufacturer's guidelines. The readout (OD ratio) was calculated by dividing the OD (measured at 450 nm) of each sample with the OD of the calibrator that was supplied with the kit.

158

159 Surrogate VNT

RBD-binding antibodies in human and animal sera were measured with the GenScript cPass 160 161 SARS-CoV-2 Neutralization Antibody Detection Kit (Genscript, the Netherlands), following the manufacturer's guidelines. Briefly, serum samples (1:10 diluted) were mixed with equal 162 163 volumes of recombinant HRP-conjugated RBD and incubated for 30 minutes at 37 °C. One hundred µL was then transferred to 96-well plates coated with recombinant hACE2 receptor 164 and incubated for 15 minutes at 37 °C. The mixture was removed, and after four automated 165 washing steps, the development solution (tetramethylbenzidine substrate, TMB) was incubated 166 for 15 minutes at room temperature, after which the stop solution was added. Absorbance was 167 measured at 450 nm and the percentage of inhibition of each sample was calculated using the 168 169 following formula: % inhibition = $(1 - (OD450 \text{ sample} / OD450 \text{ of negative control})) \times 100$. 170 Controls were included in duplicate, samples were analyzed in singular. Inhibition >30% was regarded as a positive neutralization, as suggested by the latest validation paper [29]. 171

172

174 Statistical analysis

- 175 Spearman's correlation coefficients were calculated on the sVNT inhibition percentages and
- the log2-transformed PNRT₅₀ titers or the ODratio for the Wantai Ig or IgM in SPSS 27 (IBM).
- 177 Correlation was considered significant with p values < 0.05.

179 Results and discussion

180 The performance of the commercial sVNT was evaluated by determining the correlation between the PRNT₅₀, a gold standard assay, and the sVNT. Although the initial commercial 181 182 sVNT guidelines included a cut-off of 20%, a recent validation paper now recommends a positivity cut-off at 30% of inhibition [29]. We therefore evaluated the performance of the 183 sVNT by both a 20% and 30% cut-off (Table 1). For the discussion of our results, we will focus 184 185 on the evaluation with the 30% cut-off. Using the serum panel of PCR-confirmed COVID-19 186 patients we found an overall sensitivity of 91.3 and a corresponding specificity of 100%. We found a strong increase in sensitivity of the assay with increasing PRNT₅₀ titers; sensitivity rose 187 188 from respectively 50% and 74.1% in the low-titer groups of 20 and 40, to 91.4% and above for titers of 80 and higher (Table 1, Fig. 1A). 100% sensitivity was reached for sera with titers of 189 190 160 and above. In line with the expected rise in titer during the course of disease, we found that 191 assay sensitivity increased from 88.2 to 91.0 and 96.6 when comparing the periods between 1-10, 11-21 and >21 dpd (Table 1). Overall, a significant (p < 0.001, with an Spearman's r of 192 193 0.68) correlation was observed between the two serological tests. However, the variation within 194 PRNT₅₀ groups shows that the sVNT results should be interpreted with care, since high inhibition in the sVNT is not directly translatable to high PRNT₅₀ titers (Fig. 1A). Performing 195 196 a 30%-inhibition titration of each sample would allow a more accurate comparison of both 197 assays. However, this would drastically decrease sample throughput and increase costs, which is unpreferable in diagnostic settings. 198

The results of the sVNT also showed significant correlation (p < 0.001) with OD ratios of the Wantai SARS-CoV-2 specific total Ig or IgM ELISAs, with a Spearman's r of 0.74 and 0.67 for the total Ig (Fig. 1B) and IgM (Fig. 1C) Wantai ELISA, respectively. Unfortunately, the high number of samples that reached the maximum value in both ELISAs might have affected the correlation coefficient. Closer investigation of the sera that showed a positive PRNT₅₀ result but a negative sVNT result revealed that 18 out of 21 sera were positive in the IgM Wantai and
20 out of 21 were positive in the total Ig Wantai. SARS-CoV-2 neutralizing antibodies that do
not block binding of RBD to ACE2 have been described [37], suggesting that this type of
antibodies might cause false negative results in the sVNT. Another risk for false negatives is
that this sVNT only targets RBD-binding antibodies, leaving neutralizing antibodies against
other domains of the S1- protein undetected [39,40].

The specificity of the sVNT was further investigated using a serum panel containing sera of individuals diagnosed with other coronaviruses or other (respiratory) viruses or diseases. Using this panel, we confirmed that the sVNT is 100% specific, as we did not find cross-reactivity with any of the tested sera (Fig. 1B). Two samples were found to have an inhibition between 20-30%, one serum of a HCoV-229E patient and one of an adenovirus patient. Both samples tested negative in the PRNT₅₀.

216 In parallel to the human sera, we assessed the performance of the sVNT in an elaborate panel of animal sera that included experimental model species, but also (suspected) reservoir species 217 218 (Fig. 2A). Specificity of the assay was assessed using a panel of control sera from naïve animals. 219 Sera from MERS-CoV infected cynomolgus macaques and dromedary camels were included to assess possible cross-reactivity. Similar to the results obtained with the human validation 220 221 serum panel, the sVNT showed a good performance in general, with a sensitivity of 93.9% and 222 a specificity 100%. For the rhesus macaques, ferrets, rabbits, hamsters, cats, cattle and mink we observed a 100% accurate detection of (the absence of) RBD-specific antibodies in the sera of 223 224 SARS-CoV-2 positive and negative animals.

For the cynomolgus macaques two sera of SARS-CoV-2 infected animals were found to have an inhibition between 20% and 30%, and a PRNT₅₀ titer of 40 and 80 (Fig. 2B). However, low antibody titers were expected since these animals only showed a short period of viral shedding with low levels of viral RNA in nose and trachea.

229 In agreement with the human cross-reactive serum panel, no cross-reactivity was detected in 230 serum from MERS-CoV-infected rabbits and dromedary camels. The sVNT showed a 231 sensitivity and specificity of 100% in animal sera with a PRNT₅₀ titer of 160 and above. In 232 contrast to the panel of human sera, no clear linearity was detected in the panel of animal sera 233 and large differences were observed between species. Interestingly, serum samples from ferrets, 234 rabbits and cattle with relatively low PRNT₅₀ titers (80 and below) showed a high inhibition in 235 the sVNT. Especially SARS-CoV-2-infected ferrets, where only two animals reached a PRNT₅₀ 236 titer of 80, had an inhibition of above 92%. While these high levels of inhibition in sera with a relatively low PRNT₅₀ is beneficial for detecting RBD-binding antibodies in a qualitative 237 238 manner, species-specific determination of the optimal serum dilutions is essential when the data is to be interpreted (semi-)quantitatively. The control sera of the ferrets, rabbits and cattle had 239 240 negative sVNT outcomes, indicating that the high inhibition levels were not due to background 241 or aspecific binding. Furthermore, the wide range of species-specific endemic coronaviruses 242 complicates the design of specific serological tests [41,42], and cross-reactivity needs to be 243 examined for every targeted species. While our data shows that the sVNT detects RBD-binding 244 antibodies in nine animal species, it clearly indicates that more elaborate validation is required. Validations should include higher number of sera per species, a panel of potentially cross-245 246 reactive sera, and should aim at determining optimal serum dilutions and cut-off levels.

248 Conclusion

Our results show moderate to high sensitivity and high specificity of the sVNT for detecting RBD-binding antibodies, with a 100% accuracy in sera with a PRNT₅₀ titer 160, for both human and animal sera. sVNT results should be interpreted rather qualitatively than quantitatively, since the results only show partial linearity with the PRNT₅₀ titers.

Despite the low sensitivity in detecting low titers, the sVNT still has potential use. The 253 possibility for high sample throughput makes the sVNT a suitable assay for large 254 255 seroprevalence studies that aim at detecting high titers, for example in vaccination trials or in large scale initial testing of potential animal reservoirs. While the required titer for complete 256 257 protection is still under investigation, studies have shown that with a PRNT₅₀ titer of 80 and above, no infectious virus could be detected in the respiratory tract [43]. It is thus to be expected 258 259 that threshold titers for complete protection will be in this range or higher, and as a consequence 260 the sVNT can be a valuable assay to assess protection in a qualitative manner. However, the sVNT does not serve as a full replacement of gold standard tests that use authentic virus, given 261 262 that it lacks the sensitivity to detect low titers and only targets RBD-binding antibodies.

Our evaluation shows that the sVNT also has potential use for detecting RBD-specific antibodies in animal sera, but we observed large species-dependent differences in sensitivity of the test. While in some species we observed high sVNT results in sera with low PRNT₅₀ (ferrets, rabbit, cattle), sera with low to moderate PRNT₅₀ from other species resulted in negative or low sVNT results (cynomolgus macaques). More elaborate species-specific validations are required to determine the true potential of the sVNT.

269

271 Acknowledgments

- 272 The authors acknowledge Anouskha Comvalius, Djenolan van Mourik, Jeroen Ijpelaar and
- 273 Georgina Arron for performing the PRNT₅₀, and Susanne Bogers for the sVNT testing. Robert
- 274 Jan Molenaar is acknowledged for supplying the mink sera that was included in this study.

275

276 Conflict of interest

277 The authors declare that there is no conflict of interest.

279 References

- [1] K.G. Andersen, A. Rambaut, W.I. Lipkin, E.C. Holmes, R.F. Garry, The proximal
 origin of SARS-CoV-2, Nat. Med. 26 (2020) 450–452. doi:10.1038/s41591-020-0820-
- **282** 9.
- [2] J. Zhao, W. Cui, B.P. Tian, The Potential Intermediate Hosts for SARS-CoV-2, Front.
 Microbiol. 11 (2020) 1–11. doi:10.3389/fmicb.2020.580137.
- 285 [3] P. Zhou, X. Lou Yang, X.G. Wang, B. Hu, L. Zhang, W. Zhang, H.R. Si, Y. Zhu, B.
- 286 Li, C.L. Huang, H.D. Chen, J. Chen, Y. Luo, H. Guo, R. Di Jiang, M.Q. Liu, Y. Chen,
- 287 X.R. Shen, X. Wang, X.S. Zheng, K. Zhao, Q.J. Chen, F. Deng, L.L. Liu, B. Yan, F.X.
- 288 Zhan, Y.Y. Wang, G.F. Xiao, Z.L. Shi, A pneumonia outbreak associated with a new
- 289 coronavirus of probable bat origin, Nature. 579 (2020) 270–273. doi:10.1038/s41586-
- **290** 020-2012-7.
- 291 [4] K. Xiao, J. Zhai, Y. Feng, N. Zhou, X. Zhang, J.J. Zou, N. Li, Y. Guo, X. Li, X. Shen,
- 292 Z. Zhang, F. Shu, W. Huang, Y. Li, Z. Zhang, R.A. Chen, Y.J. Wu, S.M. Peng, M.
- Huang, W.J. Xie, Q.H. Cai, F.H. Hou, W. Chen, L. Xiao, Y. Shen, Isolation of SARS-
- 294 CoV-2-related coronavirus from Malayan pangolins, Nature. 583 (2020) 286–289.
- doi:10.1038/s41586-020-2313-x.
- 296 [5] N. Oreshkova, R.J. Molenaar, S. Vreman, F. Harders, B.B. Oude Munnink, R.W.H.
- 297 Van Der Honing, N. Gerhards, P. Tolsma, R. Bouwstra, R.S. Sikkema, M.G.J. Tacken,
- 298 M.M.T. De Rooij, E. Weesendorp, M.Y. Engelsma, C.J.M. Bruschke, L.A.M. Smit, M.
- 299 Koopmans, W.H.M. Van Der Poel, A. Stegeman, SARS-CoV-2 infection in farmed
- 300 minks, the Netherlands, April and May 2020, Eurosurveillance. 25 (2020) 1–7.
- doi:10.2807/1560-7917.ES.2020.25.23.2001005.
- 302 [6] OIE, COVID-19 Events in animals, (2020). https://www.oie.int/en/scientific-
- 303 expertise/specific-information-and-recommendations/questions-and-answers-on-

304	2019novel-co	oronavirus/event	s-in-animals/	(accessed Decembe	er 10. 2	2020)

- 305 [7] B.B. Oude Munnink, R.S. Sikkema, D.F. Nieuwenhuijse, R.J. Molenaar, E. Munger, R.
- 306 Molenkamp, A. van der Spek, P. Tolsma, A. Rietveld, M. Brouwer, N. Bouwmeester-
- 307 Vincken, F. Harders, R. Hakze-van der Honing, M.C.A. Wegdam-Blans, R.J.
- 308 Bouwstra, C. GeurtsvanKessel, A.A. van der Eijk, F.C. Velkers, L.A.M. Smit, A.
- 309 Stegeman, W.H.M. van der Poel, M.P.G. Koopmans, Transmission of SARS-CoV-2 on
- 310 mink farms between humans and mink and back to humans, Science (80-.). 371 (2020)
- **311** 172–177. doi:10.1126/science.abe5901.
- 312 [8] A.V. Neira, B. Brito, B. Agüero, F. Berrios, V. Valdés, A. Gutierrez, N. Ariyama, P.
- 313 Espinoza, P. Retamal, E.C. Holmes, A.S. Gonzalez-reiche, Z. Khan, A. Van De
- 314 Guchte, J. Dutta, L. Miorin, SARS-CoV-2 in naturally infected cats present a shorter

315 shedding pattern compared to their owners., MedRxiv. (2020).

- **316** doi:10.1101/2020.10.31.20220608.
- 317 [9] E.M. Leroy, M. Ar Gouilh, J. Brugère-Picoux, The risk of SARS-CoV-2 transmission
- to pets and other wild and domestic animals strongly mandates a one-health strategy to
- control the COVID-19 pandemic, One Heal. 10 (2020) 4–7.
- doi:10.1016/j.onehlt.2020.100133.
- 321 [10] N.N. Gaudreault, J.D. Trujillo, M. Carossino, D.A. Meekins, I. Morozov, D.W.
- 322 Madden, S. V. Indran, D. Bold, V. Balaraman, T. Kwon, B.L. Artiaga, K. Cool, A.
- 323 García-Sastre, W. Ma, W.C. Wilson, J. Henningson, U.B.R. Balasuriya, J.A. Richt,
- 324 SARS-CoV-2 infection, disease and transmission in domestic cats, Emerg. Microbes
- 325 Infect. 9 (2020) 2322–2332. doi:10.1080/22221751.2020.1833687.
- 326 [11] D. McAloose, M. Laverack, L. Wang, M.L. Killian, L.C. Caserta, F. Yuan, P.K.
- 327 Mitchell, K. Queen, M.R. Mauldin, B.D. Cronk, S.L. Bartlett, J.M. Sykes, S. Zec, T.
- 328 Stokol, K. Ingerman, M.A. Delaney, R. Fredrickson, M. Ivančić, M. Jenkins-Moore, K.

- 329 Mozingo, K. Franzen, N.H. Bergeson, L. Goodman, H. Wang, Y. Fang, C. Olmstead,
- 330 C. McCann, P. Thomas, E. Goodrich, F. Elvinger, D.C. Smith, S. Tong, S. Slavinski,
- 331 P.P. Calle, K. Terio, M.K. Torchetti, D.G. Diel, From people to panthera: Natural sars-
- 332 cov-2 infection in tigers and lions at the bronx zoo, MBio. 11 (2020) 1–13.
- doi:10.1128/mBio.02220-20.
- 334 [12] S. Sooksawasdi, N. Ayudhya, T. Kuiken, Reverse Zoonosis of COVID-19 : Lessons
- From the 2009 Influenza Pandemic, Vet. Pathol. (2020).
- doi:10.1177/0300985820979843.
- 337 [13] B. Rockx, T. Kuiken, S. Herfst, T. Bestebroer, M.M. Lamers, B.B.O. Munnink, D. De
- 338 Meulder, G. Van Amerongen, J. Van Den Brand, N.M.A. Okba, D. Schipper, P. Van
- 339 Run, L. Leijten, R. Sikkema, E. Verschoor, B. Verstrepen, W. Bogers, J. Langermans,
- 340 J. Langermans, C. Drosten, M.F. Van Vlissingen, R. Fouchier, R. De Swart, M.
- 341 Koopmans, B.L. Haagmans, Comparative pathogenesis of COVID-19, MERS, and
- 342 SARS in a nonhuman primate model, Science (80-.). 368 (2020) 1012–1015.
- doi:10.1126/science.abb7314.
- 344 [14] V.J. Munster, F. Feldmann, B.N. Williamson, N. Van Doremalen, L. Pérez-pérez, J.
- 345 Schulz, K. Meade-white, A. Okumura, B. Brumbaugh, V.A. Avanzato, R. Rosenke, W.
- 346 Patrick, G. Saturday, D. Scott, E.R. Fischer, E. De Wit, Respiratory disease and virus
- 347 shedding in rhesus macaques inoculated with SARS-CoV-2, Nature. 585 (2020) 268–
- 348 272. doi:10.1038/s41586-020-2324-7.Respiratory.
- 349 [15] Y. Il Kim, S.G. Kim, S.M. Kim, E.H. Kim, S.J. Park, K.M. Yu, J.H. Chang, E.J. Kim,
- 350 S. Lee, M.A.B. Casel, J. Um, M.S. Song, H.W. Jeong, V.D. Lai, Y. Kim, B.S. Chin,
- 351 J.S. Park, K.H. Chung, S.S. Foo, H. Poo, I.P. Mo, O.J. Lee, R.J. Webby, J.U. Jung,
- 352 Y.K. Choi, Infection and Rapid Transmission of SARS-CoV-2 in Ferrets, Cell Host
- 353 Microbe. 27 (2020) 704-709.e2. doi:10.1016/j.chom.2020.03.023.

- 354 [16] J. Shi, Z. Wen, G. Zhong, H. Yang, C. Wang, B. Huang, R. Liu, X. He, L. Shuai, Z.
- 355 Sun, Y. Zhao, P. Liu, L. Liang, P. Cui, J. Wang, X. Zhang, Y. Guan, W. Tan, G. Wu,
- 356 H. Chen, Z. Bu, Z. Bu, Susceptibility of ferrets, cats, dogs, and other domesticated
- animals to SARS-coronavirus 2, Science (80-.). 368 (2020) 1016–1020.
- doi:10.1126/science.abb7015.
- 359 [17] A.Z. Mykytyn, M.M. Lamers, N.M. Okba, T.I. Breugem, P.B. van den Doel, P. van
- 360 Run, G. van Amerongen, L. de Waal, P. Koopmans, K.J. Stittelaar, J.M. van den
- 361 Brand, B.L. Haagmans, L. de Waal, K. Stittelaar, Susceptibility of rabbits to SARS-
- 362 CoV-2, BioRxiv. (2020) 2020.08.27.263988. doi:10.1080/22221751.2020.1868951.
- 363 [18] S.F. Sia, L.M. Yan, A.W.H. Chin, K. Fung, K.T. Choy, A.Y.L. Wong, P.
- 364 Kaewpreedee, R.A.P.M. Perera, L.L.M. Poon, J.M. Nicholls, M. Peiris, H.L. Yen,
- Pathogenesis and transmission of SARS-CoV-2 in golden hamsters, Nature. 583 (2020)
 834–838. doi:10.1038/s41586-020-2342-5.
- 367 [19] M. Imai, K. Iwatsuki-Horimoto, M. Hatta, S. Loeber, P.J. Halfmann, N. Nakajima, T.
- 368 Watanabe, M. Ujie, K. Takahashi, M. Ito, S. Yamada, S. Fan, S. Chiba, M. Kuroda, L.
- 369 Guan, K. Takada, T. Armbrust, A. Balogh, Y. Furusawa, M. Okuda, H. Ueki, A.
- 370 Yasuhara, Y. Sakai-Tagawa, T.J.S. Lopes, M. Kiso, S. Yamayoshi, N. Kinoshita, N.
- 371 Ohmagari, S.I. Hattori, M. Takeda, H. Mitsuya, F. Krammer, T. Suzuki, Y. Kawaoka,
- 372 Syrian hamsters as a small animal model for SARS-CoV-2 infection and
- 373 countermeasure development, Proc. Natl. Acad. Sci. U. S. A. 117 (2020) 16587–16595.
- doi:10.1073/pnas.2009799117.
- 375 [20] L. Bao, W. Deng, B. Huang, H. Gao, J. Liu, L. Ren, Q. Wei, P. Yu, Y. Xu, F. Qi, Y.
- 376 Qu, F. Li, Q. Lv, W. Wang, J. Xue, S. Gong, M. Liu, G. Wang, S. Wang, Z. Song, L.
- 377 Zhao, P. Liu, L. Zhao, F. Ye, H. Wang, W. Zhou, N. Zhu, W. Zhen, H. Yu, X. Zhang,
- 378 L. Guo, L. Chen, C. Wang, Y. Wang, X. Wang, Y. Xiao, Q. Sun, H. Liu, F. Zhu, C.

- 379 Ma, L. Yan, M. Yang, J. Han, W. Xu, W. Tan, X. Peng, Q. Jin, G. Wu, C. Qin, The
- 380pathogenicity of SARS-CoV-2 in hACE2 transgenic mice, Nature. 583 (2020) 830–
- **381** 833. doi:10.1038/s41586-020-2312-y.
- 382 [21] K. Schlottau, M. Rissmann, A. Graaf, J. Schön, J. Sehl, C. Wylezich, D. Höper, T.C.
- 383 Mettenleiter, A. Balkema-Buschmann, T. Harder, C. Grund, D. Hoffmann, A.
- 384 Breithaupt, M. Beer, SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an
- experimental transmission study, The Lancet Microbe. 1 (2020) e218–e225.
- doi:10.1016/s2666-5247(20)30089-6.
- 387 [22] J. Vergara-Alert, J. Rodon, J. Carrillo, N. Te, N. Izquierdo-Useros, M.L. Rodríguez de
- 388 la Concepción, C. Ávila-Nieto, V. Guallar, A. Valencia, G. Cantero, J. Blanco, B.
- 389 Clotet, A. Bensaid, J. Segalés, Pigs are not susceptible to SARS-CoV-2 infection but
- are a model for viral immunogenicity studies, Transbound. Emerg. Dis. (2020) 1–5.
- **391** doi:10.1111/tbed.13861.
- 392 [23] C.L. Charlton, J.N. Kanji, K. Johal, A. Bailey, S.S. Plitt, C. MacDonald, A. Kunst, E.
- Buss, L.E. Burnes, K. Fonseca, B.M. Berenger, K. Schnabl, J. Hu, W. Stokes, N.
- 394 Zelyas, G. Tipples, Evaluation of six commercial mid- To high-volume antibody and
- 395 six point-of-care lateral flow assays for detection of SARS-CoV-2 antibodies, J. Clin.
- 396 Microbiol. 58 (2020) 1–12. doi:10.1128/JCM.01361-20.
- 397 [24] T. Nicol, C. Lefeuvre, O. Serri, A. Pivert, F. Joubaud, V. Dubée, A. Kouatchet, A.
- 398 Ducancelle, F. Lunel-Fabiani, H. Le Guillou-Guillemette, Assessment of SARS-CoV-2
- serological tests for the diagnosis of COVID-19 through the evaluation of three
- 400 immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid
- 401 lateral flow immunoassay (NG Biotech), J. Clin. Virol. 129 (2020) 104511.
- 402 doi:10.1016/j.jcv.2020.104511.
- 403 [25] C.H. GeurtsvanKessel, N.M.A. Okba, Z. Igloi, S. Bogers, C.W.E. Embregts, B.M.

404		Laksono, L. Leijten, C. Rokx, B. Rijnders, J. Rahamat-Langendoen, J.P.C. van den
405		Akker, J.J.A. van Kampen, A.A. van der Eijk, R.S. van Binnendijk, B. Haagmans, M.
406		Koopmans, An evaluation of COVID-19 serological assays informs future diagnostics
407		and exposure assessment, Nat. Commun. 11 (2020) 1-5. doi:10.1038/s41467-020-
408		17317-у.
409	[26]	J. Nie, Q. Li, J. Wu, C. Zhao, H. Hao, H. Liu, L. Zhang, L. Nie, H. Qin, M. Wang, Q.
410		Lu, X. Li, Q. Sun, J. Liu, C. Fan, W. Huang, M. Xu, Y. Wang, Establishment and
411		validation of a pseudovirus neutralization assay for SARS-CoV-2, Emerg. Microbes
412		Infect. 9 (2020) 680-686. doi:10.1080/22221751.2020.1743767.
413	[27]	F. Zettl, T.L. Meister, T. Vollmer, B. Fischer, J. Steinmann, A. Krawczyk, P. V'kovski,
414		D. Todt, E. Steinmann, S. Pfaender, G. Zimmer, Rapid quantification of SARS-CoV-2-
415		neutralizing antibodies using propagation-defective vesicular stomatitis virus
416		pseudotypes, Vaccines. 8 (2020) 1-13. doi:10.3390/vaccines8030386.
417	[28]	X. Xie, A.E. Muruato, X. Zhang, K.G. Lokugamage, C.R. Fontes-Garfias, J. Zou, J.
418		Liu, P. Ren, M. Balakrishnan, T. Cihlar, C.T.K. Tseng, S. Makino, V.D. Menachery,
419		J.P. Bilello, P.Y. Shi, A nanoluciferase SARS-CoV-2 for rapid neutralization testing
420		and screening of anti-infective drugs for COVID-19, Nat. Commun. 11 (2020) 1-11.
421		doi:10.1038/s41467-020-19055-7.
422	[29]	C.W. Tan, W.N. Chia, X. Qin, P. Liu, M.I.C. Chen, C. Tiu, Z. Hu, V.C.W. Chen, B.E.
423		Young, W.R. Sia, Y.J. Tan, R. Foo, Y. Yi, D.C. Lye, D.E. Anderson, L.F. Wang, A
424		SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage
425		of ACE2-spike protein-protein interaction, Nat. Biotechnol. 38 (2020) 1073-1078.
426		doi:10.1038/s41587-020-0631-z.
427	[30]	R.A.P.M. Perera, R. Ko, O.T.Y. Tsang, D.S.C. Hui, M.Y.M. Kwan, C.J. Brackman,

428 E.M.W. To, H. Yen, K. Leung, S.M.S. Cheng, K.H. Chan, K.C.K. Chan, K.-C. Li, L.

429		Saif, V.R. Barrs, J.T. Wu, T.H.C. Sit, L.L.M. Poon, M. Peiris, Evaluation of a SARS-
430		CoV-2 surrogate virus neutralization test for detection of antibody in human, canine,
431		cat and hamster sera., J. Clin. Microbiol. (2020). doi:10.1128/jcm.02504-20.
432	[31]	C. von Rhein, T. Scholz, L. Henss, R. Kronstein-Wiedermann, T. Schwarz, R.N.
433		Rodionov, V.M. Corman, T. Tonn, B.S. Schnierle, Comparison of potency assays to
434		assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent
435		plasma, J. Virol. Methods. (2020). doi:10.1016/j.jviromet.2020.114031.
436	[32]	B. Meyer, J. Reimerink, G. Torriani, F. Brouwer, G.J. Godeke, S. Yerly, M.
437		Hoogerwerf, N. Vuilleumier, L. Kaiser, I. Eckerle, C. Reusken, Validation and clinical
438		evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT), Emerg.
439		Microbes Infect. 9 (2020) 2394–2403. doi:10.1080/22221751.2020.1835448.
440	[33]	K. Wernike, A. Aebischer, A. Michelitsch, D. Hoffmann, C. Freuling, A. Balkema-
441		Buschmann, A. Graaf, T. Müller, N. Osterrieder, M. Rissmann, D. Rubbenstroth, C.
442		Schulz, J. Trimpert, L. Ulrich, A. Volz, T. Mettenleiter, M. Beer, Multi-species ELISA
443		for the detection of antibodies against SARS-CoV-2 in animals, Transbound. Emerg.
444		Dis. (2020). doi:10.1111/tbed.13926.
445	[34]	J. Deng, Y. Jin, Y. Liu, J. Sun, L. Hao, J. Bai, T. Huang, D. Lin, Y. Jin, K. Tian,
446		Serological survey of SARS-CoV-2 for experimental, domestic, companion and wild
447		animals excludes intermediate hosts of 35 different species of animals, Transbound.
448		Emerg. Dis. 67 (2020) 1745–1749. doi:10.1111/tbed.13577.
449	[35]	S.N. Walker, N. Chokkalingam, E.L. Reuschel, M. Purwar, Z. Xu, E.N. Gary, K.Y.
450		Kim, M. Helble, K. Schultheis, J. Walters, S. Ramos, K. Muthumani, T.R.F. Smith,
451		K.E. Broderick, P. Tebas, A. Patel, D.B. Weiner, D.W. Kulp, SARS-CoV-2 Assays to
452		Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated
453		Animals and Infected Patients, J. Clin. Microbiol. 58 (2020) 1-13.

454 doi:10.1128/JCM.01533-20.

- 455 [36] R.D. de Vries, K.S. Schmitz, F.T. Bovier, D. Noack, B.L. Haagmans, S. Biswas, B.
- 456 Rockx, S.H. Gellman, C.A. Alabi, R.L. de Swart, A. MOSCONA, M. Porotto,
- 457 Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2
- 458 transmission in ferrets, Science (80-.). (2021) 2020.11.04.361154.
- doi:10.1126/science.abf4896.
- 460 [37] C. Wang, W. Li, D. Drabek, N.M.A. Okba, R. van Haperen, A.D.M.E. Osterhaus,
- 461 F.J.M. van Kuppeveld, B.L. Haagmans, F. Grosveld, B.J. Bosch, A human monoclonal
- 462 antibody blocking SARS-CoV-2 infection, Nat. Commun. 11 (2020) 1–6.
- 463 doi:10.1038/s41467-020-16256-y.
- 464 [38] N.M.A. Okba, M.A. Müller, W. Li, C. Wang, C.H. Geurtsvankessel, V.M. Corman,
- 465 M.M. Lamers, R.S. Sikkema, E. De Bruin, F.D. Chandler, Y. Yazdanpanah, Q. Le
- 466 Hingrat, D. Descamps, N. Houhou-Fidouh, C.B.E.M. Reusken, B.J. Bosch, C. Drosten,
- 467 M.P.G. Koopmans, B.L. Haagmans, Severe Acute Respiratory Syndrome Coronavirus
- 468 2-Specific Antibody Responses in Coronavirus Disease Patients, Emerg. Infect. Dis. 26
- 469 (2020) 1478–1488. doi:10.3201/eid2607.200841.
- 470 [39] L. Liu, P. Wang, M.S. Nair, J. Yu, M. Rapp, Q. Wang, Y. Luo, J.F.W. Chan, V. Sahi,
- 471 A. Figueroa, X. V. Guo, G. Cerutti, J. Bimela, J. Gorman, T. Zhou, Z. Chen, K.Y.
- 472 Yuen, P.D. Kwong, J.G. Sodroski, M.T. Yin, Z. Sheng, Y. Huang, L. Shapiro, D.D.
- 473 Ho, Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike,
- 474 Nature. 584 (2020) 450–456. doi:10.1038/s41586-020-2571-7.
- 475 [40] X. Chi, R. Yan, J. Zhang, G. Zhang, Y. Zhang, M. Hao, Z. Zhang, P. Fan, Y. Dong, Y.
- 476 Yang, Z. Chen, Y. Guo, J. Zhang, Y. Li, X. Song, Y. Chen, L. Xia, L. Fu, L. Hou, J.
- 477 Xu, C. Yu, J. Li, Q. Zhou, W. Chen, A neutralizing human antibody binds to the N-
- 478 terminal domain of the Spike protein of SARS-CoV-2, Science (80-.). 369 (2020)

479 650–655. doi:10.1126/science.abc6952.

- 480 [41] A.N. Vlasova, X. Zhang, M. Hasoksuz, H.S. Nagesha, L.M. Haynes, Y. Fang, S. Lu,
- 481 L.J. Saif, Two-Way Antigenic Cross-Reactivity between Severe Acute Respiratory
- 482 Syndrome Coronavirus (SARS-CoV) and Group 1 Animal CoVs Is Mediated through
- 483 an Antigenic Site in the N-Terminal Region of the SARS-CoV Nucleoprotein, J. Virol.
- 484 81 (2007) 13365–13377. doi:10.1128/jvi.01169-07.
- 485 [42] Z.F. Sun, X.J. Meng, Antigenic Cross-Reactivity between the Nucleocapsid Protein of
- 486 Severe Acute Respiratory Syndrome (SARS) Coronavirus and Polyclonal Antisera of
- 487 Antigenic Group I Animal Coronaviruses: Implication for SARS Diagnosis [2], J. Clin.

488 Microbiol. 42 (2004) 2351–2352. doi:10.1128/JCM.42.5.2351-2352.2004.

- 489 [43] J. van Kampen, D. van de Vijver, P. Fraaij, B. Haagmans, M. Lamers, N. Okba, J. van
- 490 den Akker, H. Endeman, D. Gommers, J. Cornelissen, R. Hoek, M. van der Eerden, D.
- 491 Hesselink, H. Metselaar, A. Verbon, J. de Steenwinkel, G. Aron, E. van Gorp, S. van

Boheemen, J. Voermans, C. Boucher, R. Molenkamp, M. Koopmans, C.

- 493 Geurtsvankessel, A. van der Eijk, Shedding of infectious virus in hospitalized patients
- 494 with coronavirus disease-2019 (COVID-19): duration and key determinants, Nat.

495 Commun. 12 (2021). doi:10.1101/2020.06.08.20125310.

- 496 [44] B.L. Haagmans, D. Noack, N.M.A. Okba, W. Li, T. Besteboer, R. de Vries, S. Herfst,
- 497 D. de Meulder, P. van Run, M.M. Lamers, B. Rijnders, C. Rokx, F. van Kuppeveld, F.
- 498 Grosveld, D. Drabek, C. GeurtsvanKessel, M. Koopmans, B.-J. Bosch, B. Rockx,
- 499 SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract
- 500 disease in a hamster model, BioRxiv. (2020). doi:10.1101/2020.08.24.264630.
- 501 [45] L. Ulrich, K. Wernike, D. Hoffmann, T.C. Mettenleiter, M. Beer, Experimental
- 502 infection of cattle with SARS-CoV-2, Emerg. Infect. Dis. 26 (2020) 2979–2981.
- 503 doi:10.3201/EID2612.203799.

- 504 [46] B.L. Haagmans, S.H.S. Al Dhahiry, C.B.E.M. Reusken, V.S. Raj, M. Galiano, R.
- 505 Myers, G.J. Godeke, M. Jonges, E. Farag, A. Diab, H. Ghobashy, F. Alhajri, M. Al-
- 506 Thani, S.A. Al-Marri, H.E. Al Romaihi, A. Al Khal, A. Bermingham, A.D.M.E.
- 507 Osterhaus, M.M. AlHajri, M.P.G. Koopmans, Middle East respiratory syndrome
- 508 coronavirus in dromedary camels: An outbreak investigation, Lancet Infect. Dis. 14
- 509 (2014) 140–145. doi:10.1016/S1473-3099(13)70690-X.
- 510
- 511

512 Figures

513



Fig. 1. sVNT results using the human validation panel containing confirmed COVID-19 patients compared to the PRNT₅₀ (A), the total Ig Wantai ELISA (B) or the IgM Wantai ELISA (C). sVNT results using the cross-reactive human serum panel are shown in (D). Each dot represents an individual serum. Dotted grey lines indicate the suggested cut-off values for the presented assays. The grey lines in (A), (B) and (C) show the Spearman's correlation coefficient (*r*) and its confidence interval (grey area) of the PRNT₅₀ / Wantai ELISAs and the sVNT.



Fig. 2. sVNT results obtained with sera of SARS-CoV-2-infected animals, MERS-CoV-infected animals or control animals, grouped by animal species and seroconversion status (positive vs. negative, (A)), or PRNT₅₀ titer (B). Each dot represents an individual serum.
Dotted horizontal lines indicate the suggested 20% and 30% inhibition cut-off values. Cats were excluded in (B) since no PRNT₅₀ were available.

532 Tables

Table 1: Sensitivity and specificity analysis of the sVNT using a 20% inhibition cut-off [upper part] or 30%
cut-off of inhibition [lower part].

535

				D	pd					Т	iters P	RNT50)			
	Group	All	Un- known	<11	11-21	>21	<20	20	40	80	160	320	640	1280	2560	>2560
PRNT50/ sVNT	+/+	226	22	27	63	114	0	12	23	34	33	26	35	29	23	11
	+/-	15	2	7	4	2	0	10	4	1	0	0	0	0	0	0
	_/+	3	0	1	0	2	3	0	0	0	0	0	0	0	0	0
	-/-	54	5	31	16	2	54	0	0	0	0	0	0	0	0	0
	n samples	298	29	66	83	120	57	22	27	35	33	26	35	29	23	11
	n patients	165	27	31	48	121										
Sensitivity [%] Specificity		93.8	91.7	79.4	94.0	98.3		54.5	85.2	97.1	100	100	100	100	100	100
[%]		94.7		96.9	100.0	50.0	94.7									

				D	nd					т	itors D	DNT.				
				D	pu					1	ILCIS F	KIN15)			
	Group	All	Unknown	<11	11-21	>21	<20	20	40	80	160	320	640	1280	2560	>2560
PRNT50/sVNT	+/+	220	22	30	61	112	0	11	20	32	33	26	35	29	23	11
	+/-	21	2	4	6	4	0	11	7	3	0	0	0	0	0	0
	_/+	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	-/-	57	5	32	16	4	57	0	0	0	0	0	0	0	0	0
	n samples	298	29	66	83	120	57	22	27	35	33	26	35	29	23	11
	n patients	165	27	31	48	121										
Sensitivity [%]		91.3	91.7	88.2	91.0	96.6		50.0	74.1	91.4	100	100	100	100	100	100
Specificity [%]		100	100	100	100	100	100									

536

Table 2. Sensitivity and specificity analysis of the sVNT using an animal serum panel of nine

539 different species, including SARS-CoV and MERS-CoV positive animals and control animals.

540

	SARS-CoV-2							
	Seropos	sitive	Seroneg	ative				
	20%	30%	20%	30%				
Cynomolgus macaques	11/13	9/13	10/10	10/10				
Rhesus macaques	9/9	9/9	10/10	10/10				
Ferrets	16/16	16/16	11/11	11/11				
Rabbits	7/7	7/7	14/14	14/14				
Hamsters	4/4	4/4	4/4	4/4				
Cats	6/6	6/6	9/10	10/10				
Cattle	1/1	1/1	10/10	10/10				
Mink	10/10	10/10	-	-				
MERS-CoV-seropositive								
Dromedary camels			13/13	13/13				
Cynomolgus macaques			2/2	2/2				

	Sensitiv	vity	Specifi	icity	
	20%	30%	20%	30%	
All data	97.0	93.9	99.07	100	
PRNT ₅₀ 20-80	92.9	85.7			
PRNT ₅₀ >80	100	100			

541

Supplementary tables

Supplementary table 1. Overview of the human COVID-19 validation serum panel.

		Age	Sex			Dpd	Outcome			
	Ν	Mean [range]	Female	Male	Unknown	Mean [range]*	Discharged	Deceased	Unknown	
All	298	53 [15-90]	61	216	21	26 [0-74]	94	48	156	
Mild	132	51 [15-66]	25	88	19	25 [0-74]	2	0	130	
Ward	61	52 [25-90]	14	45	2	25 [2-65]	23	19	19	
ICU	105	52 [17-83]	22	83	0	24 [0-41]	69	29	7	

* 29 samples had an unknown dpd

Supplementary table 2. Overview of sera included in the animal serum validation panel.

	SARS-CoV-2	Control	Other	Total	Reference
Cynomolgus macaques	13	14	2 [MERS-CoV]	29	[13, unpublished]
Rhesus macaques	9	10		19	unpublished
Ferrets	16	11		27	[36, unpublished]
Rabbits	7	14		21	[17,33]
Hamsters	4	4		8	[44]
Cats	6	10		16	[5]
Cattle	1	10		11	[45]
Mink	10	0		10	unpublished
Dromedary camels	0	0	13 [MERS-CoV]	13	[46]
	66	73	15	154	